Oppenheimer Initiates Coverage of Complete Genomics with 'Outperform' Rating | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm Oppenheimer initiated coverage of Complete Genomics on Thursday with an "Outperform" rating and a share target price of $13.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.